Recombinant Parvovirus B19 (aa 1 - 781) (DAG-P2515)

Parvovirus B19 (aa 1 - 781), recombinant protein from Baculovirus

Product Overview
Parvovirus B19 full length protein
Nature
Recombinant
Tag/Conjugate
Unconjugated
Molecular Weight
86 kDa
Procedure
None
Purity
> 80 % by SDS-PAGE.The protein is purified by proprietary chromatographic technique.
Format
Liquid
Buffer
pH: 7.4Constituents: 0.26% Sodium phosphate, 0.7% Sodium chloride, 20% Glycerol
Preservative
None
Storage
Shipped at 4°C. Store at -20°C. Avoid freeze / thaw cycle. pH: 7.4Constituents: 0.26% Sodium phosphate, 0.7% Sodium chloride, 20% Glycerol
Introduction
Parvoviruses cause infections in a wide variety of birds and mammals. Parvovirus, commonly called parvo, is a genus of the Parvoviridae family linear, non-segmented single stranded DNA viruses with an average genome size of 5 kbp. Parvoviruses are some of
Antigen Description
Parvovirus B19 infection is common among children and adults and is often asymptomatic. Parvovirus B19 infection can result in serious and occasionally fatal hematologic diseases in susceptible patients, and is the cause of "fifth disease", a highly contagious infection of childhood. Parvovirus B19 can also infect the fetus causing severe anemia, congestive heart failure, and death in utero or at birth.
Keywords
Parvovirus B19

Citations


Have you cited DAG-P2515 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Parvovirus B19 infection mimicking systemic lupus erythematosus, successfully treated with intravenous immune globulin

GERMS

Authors: Ozlu, Sare Gulfem; Alan, Basak; Sahiner, Aysegul; Bulut, Busra; Bayhan, Gulsum Iclal; Ozdemir, Sonay Incesoy

Introduction Parvovirus B19 infection generally presents as a transient viral illness in children but rarely shows systemic lupus erythematosus-like symptoms. Case report Here we present a 7-year-old girl with parvovirus B19 infection who had prolonged fever, rash, pancytopenia and hypocomplementemia making it difficult do differentiate from the first episode of systemic lupus erythematosus. Because she had severe progressive pancytopenia she was administered intravenous immune globulin treatment and her clinical course was dramatically improved. Discussion Parvovirus B19 infection can mimic systemic lupus erythematosus and it may be difficult to differentiate a recent parvovirus B19 infection and the first presentation of systemic lupus erythematosus. Absence of discoid lesions, alopecia, Raynaud phenomenon and autoimmune hemolytic anemia may help to distinguish parvovirus B19 infection from systemic lupus erythematosus. Conclusions Parvovirus B19 infection may cause a severe clinical picture resembling systemic lupus erythematosus even in otherwise healthy children. Intravenous immune globulin treatment might be considered in cases resistant to supportive management.

Highly Effective Fibrin Biopolymer Scaffold for Stem Cells Upgrading Bone Regeneration

MATERIALS

Authors: Creste, Camila Fernanda Zorzella; Orsi, Patricia Rodrigues; Landim-Alvarenga, Fernanda Cruz; Justulin, Luis Antonio; Golim, Marjorie de Assis; Barraviera, Benedito; Ferreira, Rui Seabra

Fibrin scaffold fits as a provisional platform promoting cell migration and proliferation, angiogenesis, connective tissue formation and growth factors stimulation. We evaluated a unique heterologous fibrin biopolymer as scaffold to mesenchymal stem cells (MSCs) to treat a critical-size bone defect. Femurs of 27 rats were treated with fibrin biopolymer (FBP); FBP + MSCs; and FBP + MSC differentiated in bone lineage (MSC-D). Bone repair was evaluated 03, 21 and 42 days later by radiographic, histological and scanning electron microscopy (SEM) imaging. The FBP + MSC-D association was the most effective treatment, since newly formed Bone was more abundant and early matured in just 21 days. We concluded that FBP is an excellent scaffold for MSCs and also use of differentiated cells should be encouraged in regenerative therapy researches. The FBP ability to maintain viable MSCs at Bone defect site has modified inflammatory environment and accelerating their regeneration.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket